Regalia Pharmaceutical (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-12-2024
- Paid Up Capital ₹ 0.77 M
as on 04-12-2024
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 2.00 M
as on 04-12-2024
- Revenue 21.37%
(FY 2022)
- Profit 88.92%
(FY 2022)
- Ebitda 91.76%
(FY 2022)
- Net Worth
- Total Assets 1.24%
(FY 2022)
About Regalia Pharmaceutical (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.77 M.
The company currently has active open charges totaling ₹2.00 M.
Rohit Karpe and Anil Belkar serve as directors at the Company.
- CIN/LLPIN
U24232PN2007PTC130885
- Company No.
130885
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2007
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Regalia Pharmaceutical (India) Private Limited offer?
Regalia Pharmaceutical (India) Private Limited offers a wide range of products and services, including Multivitamin Syrup & Drops, Ferrous Ascorbate Syrup, Diclofenac, Diclofenac Sodium Injection, Antibiotic Injection, Piperacillin Tazobactam Injection, Common Disease Medicines, Steroid, Mineral Supplement, Iron Syrup.
Who are the key members and board of directors at Regalia Pharmaceutical (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Karpe  | Director | 20-Oct-2007 | Current |
| Anil Belkar | Additional Director | 31-Mar-2023 | Current |
Financial of Regalia Pharmaceutical (India).
Regalia Pharmaceutical (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 21.37% increase. The company also saw a substantial improvement in profitability, with a 88.92% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regalia Pharmaceutical (India)?
In 2022, Regalia Pharmaceutical (India) had a promoter holding of 87.95% and a public holding of 12.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 08 Jul 2016 | ₹2.00 M | Open |
How Many Employees Work at Regalia Pharmaceutical (India)?
Regalia Pharmaceutical (India) has a workforce of 10 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regalia Pharmaceutical (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regalia Pharmaceutical (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
